SAN DIEGO, March 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback